Our data substantiated the participation of CDK4/6 inhibition in iCCA and validated our hypothesis, providing the theoretical basis for the development of combination therapy, for instance, with the PI3K pathway inhibitor PF-04691502. Here, CDK4 is linked to infantile convulsions and choreoathetosis.